Search results for "CTAB"

showing 10 items of 231 documents

Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion

2002

BACKGROUND Cancer pain emergencies presenting with severe excruciating pain require a rapid application of powerful analgesic strategies. The aim of the current study was to evaluate a method of rapid titration with intravenous morphine to achieve relief of cancer pain of severe intensity. METHODS Forty-nine consecutive patients admitted to a Pain Relief and Palliative Care Unit for severe and prolonged pain were enrolled in the study. Pain was evaluated on a numeric scale of 0–10 (0 indicated no pain and 10 indicated excruciating pain). After the initial assessment (T0), an intravenous line was inserted and boluses of morphine (2 mg every 2 minutes) were given until the initial signs of si…

MaleCancer Researchmedicine.medical_specialtyPalliative careAnalgesicAdministration OralOpioidInjections IntravenouNursing careRoute of administrationMorphine titrationOral administrationNeoplasmsmedicineHumansEpidemiologic studyCancer painAdverse effectMorphinebusiness.industryIntravenous routeMiddle AgedPain IntractableSurgeryAnalgesics OpioidOncologyAnesthesiaPain emergencieInjections IntravenousMorphineNeoplasmFemalebusinessCancer painHumanmedicine.drugCancer
researchProduct

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

Predictability of pharmaceutical spending in primary health services using Clinical Risk Groups

2014

Background: Risk adjustment instruments applied to existing electronic health records and administrative datasets may contribute to monitoring the correct prescribing of medicines. Objective: We aim to test the suitability of the model based on the CRG system and obtain specific adjusted weights for determined health states through a predictive model of pharmaceutical expenditure in primary health care. Methods: A database of 261,054 population in one health district of an Eastern region of Spain was used. The predictive power of two models was compared. The first model (ATC-model) used nine dummy variables: sex and 8 groups from 1 to 8 or more chronic conditions while in the second model (…

MaleECONOMIA APLICADAHealth StatusPopulationContext (language use)Pharmacy expenditureDrug CostsSex FactorsDrug TherapyDummy variablePrimary healthMedicineHumansPredictabilityeducationeducation.field_of_studyActuarial scienceModels StatisticalPrimary Health Carebusiness.industryHealth PolicyClinical Risk GroupsAge FactorsECONOMIA SOCIOLOGIA Y POLITICA AGRARIATest (assessment)Risk adjustmentOne HealthSpainChronic DiseasePredictive powerFemalebusinessWHO-ATC-Code
researchProduct

Minimal clinically important difference and minimal detectable change of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0…

2020

Objectives: The aim of this study is to estimate a minimal clinically important difference (MCID) and a minimal detectable change (MDC) of the 12-item WHODAS 2.0 amongst patients with chronic musculoskeletal pain. Design: Cross-sectional cohort study. Setting: Outpatient Physical and Rehabilitation Medicine clinic. Subjects: A total of 1988 consecutive patients with musculoskeletal pain. Interventions: A distribution-based approach was employed to estimate a minimal clinically important difference, a minimal detectable change, and a minimal detectable percent change (MDC%). Results: The mean age of the patients was 48 years, and 65% were women. The average intensity of pain was 6,3 (2.0) po…

MaleMusculoskeletal painSchedule2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WHODASPhysical Therapy Sports Therapy and Rehabilitationminimal detectable changetuki- ja liikuntaelimetWorld healthDisability assessmentCohort StudiesDisability EvaluationMusculoskeletal PainHumansMedicineskin and connective tissue diseasesmusculoskeletal painPain Measurementbusiness.industryMinimal clinically important differenceminimal clinically important differenceRehabilitationkipuMiddle AgedCross-Sectional StudiesPhysical therapyFemalesense organsWhodasChronic PainbusinessData Collection toolsClinical Rehabilitation
researchProduct

Methadone response in advanced cancer patients with pain followed at home

1999

Concerns about the safety of therapy with methadone, which may arise because of its pharmacokinetic characteristics and inappropriate dosing, may deter clinicians from using this drug, especially in elderly patients. Experience is accumulating that the drug may be used safely and successfully if low doses are given initially and care is taken in the titration of the dose against the pain. A prospective study was carried out in a consecutive sample of 45 advanced cancer patients followed at home, who had never received other strong opioids for their pain. Patients were treated with an oral liquid preparation of methadone, which was administered 2-3 times daily, according to need. Doses were …

MaleOpioidAdverse effectSex FactorsNeoplasmsHumansMedicineProspective StudiesDosingCancer painAdverse effectProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain Measurementbusiness.industryMiddle AgedHome Care ServicesMiddle agePain IntractableAnalgesics OpioidAnesthesiology and Pain MedicineAnesthesiaNeuropathic painAmbulatoryFemaleNeurology (clinical)businessCancer painMethadoneMethadonemedicine.drug
researchProduct

Ineffectiveness of dextromethorphan in cancer pain

1998

Experimental studies have indicated that N-methyl-D-aspartate (NMDA) receptor antagonists may be effective analgesics in a wide variety of chronic pain states. The mechanism is presumed to be related to decreased firing of dorsal horn neurons after constant repeated C-fiber stimulation. Dextromethorphan (DM), a potent NMDA antagonist with a good safety profile, may be a promising agent for the treatment of persistent pain. An open-label randomized trial was designed to examine the effects of combining DM with NSAIDs, dextropropoxyphene, or morphine in cancer patients with pain. Patients who required a change in the step of the World Health Organization's (WHO) analgesic ladder because of a …

MalePalliative careAnalgesicNeuropathic painDextromethorphanNeoplasmsWHO methodmedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)DextropropoxypheneMorphinebusiness.industryPalliative CareChronic painPain scaleMiddle Agedmedicine.diseasePain IntractableAnalgesics OpioidAnesthesiology and Pain MedicineOpioidAnesthesiaNeuropathic painDrug Therapy CombinationFemaleIntractable painNeurology (clinical)businessCancer painExcitatory Amino Acid Antagonistsmedicine.drug
researchProduct

Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic…

2021

Background Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses. Objective Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors. Methods The STAR Network ‘Depot Study’ was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions …

MalePediatricsrespectively)0302 clinical medicineDelayed-Action PreparationBrief Psychiatric Rating ScalePharmacology (medical)he STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in ItalyOriginal Research ArticleProspective StudiesProspective cohort studytreatmentMental DisordersHazard ratiowhereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5%Psychiatric Status Rating ScaleMiddle Agedside efectsPsychiatry and Mental healthItalyMental DisorderFemalehe STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in Italy occurring in almost 40% of the entire sample; side efects participant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4% respectively) whereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5% respectively). In multivariate analysis being prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation risk.HumanAntipsychotic Agentsmedicine.drugPsychopathologyAdultmedicine.medical_specialtyDiscontinuationFollow-Up StudieMedication Adherence03 medical and health sciencesmedicineHumansPaliperidoneAdverse effectSettore MED/25 - Psichiatriadiscontinuation ratesPsychiatric Status Rating Scalesrespectively). In multivariate analysisbusiness.industryLong-Acting Antipsychoticlong-acting injectable antipsychoticsSurvival AnalysisConfidence intervalparticipant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4%030227 psychiatryDiscontinuationProspective StudieAntipsychotic Agentoccurring in almost 40% of the entire sampleDelayed-Action PreparationsNeurology (clinical)business030217 neurology & neurosurgerybeing prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation riskFollow-Up Studies
researchProduct

Fractal analyses reveal independent complexity and predictability of gait

2017

Locomotion is a natural task that has been assessed since decades and used as a proxy to highlight impairments of various origins. Most studies adopted classical linear analyses of spatio-temporal gait parameters. Here, we use more advanced, yet not less practical, non-linear techniques to analyse gait time series of healthy subjects. We aimed at finding more sensitive indexes related to spatio-temporal gait parameters than those previously used, with the hope to better identify abnormal locomotion. We analysed large-scale stride interval time series and mean step width in 34 participants while altering walking direction (forward vs. backward walking) and with or without galvanic vestibular…

MalePhysiologyEffect of gait parameters on energetic costlcsh:MedicineWalkingMotor Neuron Diseases0302 clinical medicineElderlyMedicine and Health SciencesMastoid Processlcsh:ScienceMusculoskeletal SystemGaitMathematicsMultidisciplinary05 social sciencesNeurodegenerative DiseasesFractalsNeurologyPhysical SciencesFemale[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]AnatomyGait AnalysisResearch ArticleAdultSTRIDEGeometryFOS: Physical sciencesSurgical and Invasive Medical ProceduresFractal dimension050105 experimental psychology03 medical and health sciencesYoung AdultFractalHumans0501 psychology and cognitive sciencesPredictabilityGalvanic vestibular stimulationSkeletonHurst exponentFunctional Electrical Stimulationbusiness.industryBiological LocomotionAmyotrophic Lateral SclerosisSkulllcsh:RBiology and Life SciencesPattern recognitionPhysics - Medical PhysicsAge GroupsGait analysis[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]People and PlacesPopulation Groupingslcsh:QArtificial intelligenceMedical Physics (physics.med-ph)business030217 neurology & neurosurgeryMathematics
researchProduct

Opioid plasma concentration during switching from morphine to methadone: Preliminary data

2003

Opioid switching is often used to improve the opioid response in cancer patients experiencing poor analgesia or adverse effects. However, no data are available on plasmatic changes of opioids and their metabolites during these phases, and whether there exists a relationship with the clinical events. In a prospective study of 10 consecutive cancer patients on oral morphine but with uncontrolled pain (greater >4 on a numerical scale of 0 to 10) and/or moderate to severe opioid adverse effects (on a level of 2 and 3 of a verbal scale) and not responsive to adjuvant medications, switching to oral methadone was performed using a fixed ratio of 5:1, leaving extra-doses of 1/5 of the daily dose of…

MaleTime FactorsAdministration OralAdverse effectDrug Administration ScheduleNeoplasmsBlood plasmamedicineHumansProspective StudiesCancer painProspective studyProspective cohort studyAdverse effectAgedDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidOncologyAnesthesiaToxicitySwitchingMorphineFemaleAnalgesiabusinessCancer painMethadonemedicine.drugMethadone
researchProduct

Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study

2015

Background: Reduction of tibial plateau fractures and maintain a level of well aligned congruent joint is key to a satisfactory clinical outcome and is important for the return to pre-trauma level of activity. Stable internal fixation support early mobility and weight bearing. The augmentation with bone graft substitute is often required to support the fixation to mantain reduction. For these reasons there has been development of novel bone graft substitutes for trauma applications and in particular synthetic materials based on calcium phosphates and/or apatite combined with calcium sulfates. Injectable bone substitutes can optimize the filling of irregular bone defects. The purpose of this…

MaleTime FactorsPercutaneousKnee Jointmedicine.medical_treatmentDentistryFracture Fixation InternalFracture FixationTibial plateau fracture Surgical treatment Bone graft Ceramic injectable biphasic bone substitute Clinical and radiographic outcomeFracture fixationTibial plateau fractureOrthopedics and Sports MedicineProspective StudiesTomographyFracture HealingSurgical treatmentBone TransplantationMiddle AgedCombined Modality TherapyBiomechanical PhenomenaX-Ray ComputedDrug CombinationsTreatment Outcomemedicine.anatomical_structureSettore MED/03FemaleResearch ArticleAdultmedicine.medical_specialtyBone healingCalcium SulfateInjectionsRheumatologyClinical and radiographic outcomeTibial plateau fracturemedicineBone graftHumansInternal fixationTibiaTibiabusiness.industryRecovery of Functionmedicine.diseaseInternalSurgeryTibial FracturesDurapatiteCeramic injectable biphasic bone substituteIrregular boneBone SubstitutesOrthopedic surgeryAdult; Biomechanical Phenomena; Bone Substitutes; Bone Transplantation; Calcium Sulfate; Combined Modality Therapy; Drug Combinations; Durapatite; Female; Follow-Up Studies; Fracture Fixation Internal; Fracture Healing; Humans; Injections; Knee Joint; Male; Middle Aged; Prospective Studies; Recovery of Function; Tibia; Tibial Fractures; Time Factors; Tomography X-Ray Computed; Treatment OutcomeTomography X-Ray ComputedbusinessFollow-Up StudiesBMC Musculoskeletal Disorders
researchProduct